Q2 2025 Genomma Lab Internacional SAB de CV Earnings Call Transcript
Key Points
- Genomma Lab Internacional SAB de CV (GNMLF) reported a 4.4% EBITDA growth with an 89 basis points margin expansion to 23.8%, driven by ongoing productivity programs.
- Pro forma net income increased by 16.6% when excluding noncash effects from hyperinflationary accounting adjustments.
- The company achieved a 64% increase in free cash flow, reaching 2.7 million in the trailing 12 months, supported by a 7-day improvement in the cash conversion cycle.
- Genomma Lab Internacional SAB de CV (GNMLF) maintained or gained market share in 67% of its sales and outpaced inflation in 75% of its sales.
- The company plans to open 120 new distribution routes in Mexico over the next 12 months, targeting higher temperature areas to mitigate weather impacts.
- Second quarter sales grew only 0.5%, significantly impacted by an 18.8% depreciation of the Argentine peso and a weak beverage season in Mexico.
- Net income was negatively affected by hyperinflationary accounting adjustments due to the Argentine peso depreciation.
- The beverage division in Mexico faced challenges due to a minus 2.4 degree Celsius drop in average temperatures, impacting isotonic category performance.
- The US market is not expected to recover into growth this year due to disrupted Hispanic consumption.
- The company anticipates ongoing headwinds and hyperinflationary adjustments to bring full-year sales growth to near 0, with a projected single-digit contraction in the weakest quarter.
Greetings, ladies and gentlemen. Thank you for joining Genomma Lab's Second Quarter 2025 Earnings Conference Call. (Operator Instructions). As a reminder, this meeting is being recorded and will be available for replay from the Investor Relations section of Genomma's website following the call. I will now turn the call over to Christianne Ibanez, Genomma's Head of Investor Relations. Please go ahead.
Thank you, and welcome, everyone. On today's call are Marco Sparvieri, Chief Executive Officer; and Antonio Zamora, Chief Financial Officer. Before we get started, I'd like to remind you that the remarks today will include forward-looking statements such as the company's financial guidance and expectations, including long-term objectives and forecasts as well as expectations regarding Genomma's business, assets, products, strategies, demand and markets.
These statements are subject to risks and uncertainties that could cause actual results to differ materially. They are also based
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
